Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor.
D000328:Adult; D000368:Aged; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005069:Evaluation Studies as Topic; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid*; D007989:Libido / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000378:metabolism; D010648:Phenylacetates / Q000134:cerebrospinal fluid*; D011339:Probenecid / Q000627:therapeutic use; D012701:Serotonin / Q000378:metabolism
D006834:Hydrazines; D010648:Phenylacetates; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D004295:Dihydroxyphenylalanine; D002262:Carboxy-Lyases; D011339:Probenecid; D004298:Dopamine; D006719:Homovanillic Acid